Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.
253 - 258.
To estimate the cost utility of treatment with combination therapy (ribavirin and interferon alpha) for hepatitis C compared with no treatment or monotherapy (interferon alpha) based on UK costs and clinical management.
|Title:||Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.|
|Keywords:||Adult, Aged, Antiviral Agents, Cohort Studies, Cost-Benefit Analysis, Decision Support Techniques, Drug Combinations, Female, Health Resources, Health Status, Hepatitis C, Chronic, Humans, Interferon-alpha, Liver Transplantation, Male, Markov Chains, Middle Aged, Quality-Adjusted Life Years, Ribavirin, Sensitivity and Specificity|
Archive Staff Only